02771nam1 22004693i 450 PUV098238820231121125620.0888450130X20160401d2004 ||||0itac50 balatitaitz01i xxxe z01nDerivationesUguccione da Pisaedizione critica princeps a cura di Enzo Cecchini e di Guido Arbizzoni ... [et al.]FirenzeSismel-Edizioni del Galluzzo20042 v.25 cm.Edizione nazionale dei testi mediolatini11. Serie 16001MIL05622952001 Edizione nazionale dei testi mediolatini. Serie 16001PUV09937232000 1Uguccione da Pisa1001PUV09937272000 2Uguccione da Pisa2477LINGUA LATINA ARCAICA, POSTCLASSICA, VOLGARE21477.03LATINO ARCAICO, POSTCLASSICO, VOLGARE. Dizionari, enciclopedie, concordanze21Uguccione : da PisaUFIV046534070290080Cecchini, Enzo <1929- >AQ1V001084Arbizzoni, GuidoCFIV017320Uguccio <vescovo di Ferrara>CFIV181095Uguccione : da PisaHuguccioCFIV181096Uguccione : da PisaHugoCFIV181097Uguccione : da PisaITIT-0120160401IT-RM028 IT-RM0289 IT-RM0290 IT-RM0313 IT-RM0281 IT-RM0151 IT-FR0017 Biblioteca Universitaria AlessandrinaRM028 Biblioteca Statale A. BaldiniRM0289 BIBLIOTECA ANGELICARM0290 BIBLIOTECA CASANATENSERM0313 BIBLIOTECA VALLICELLIANARM0281 Biblioteca Istituto Storico Italiano Medio Evo - IRM0151 Biblioteca umanistica Giorgio ApreaFR0017 PUV0982388Biblioteca umanistica Giorgio Aprea 52MAG 11/1363.2 52MAG 11/1363.1 52CIS 3/65.1 52VM 0000530975 VM barcode:00021299. - Inventario:27576 FLSVMA 2005021820121204 52CIS 3/65.2 52VM 0000530965 VM barcode:00021298. - Inventario:27577 FLSVMA 2005021820121204VOL. 2. 52COBAL C.M. 424 (2.2) 52VP 0000190685 VM Inventario:3060ATENEO Descr.Fascicoli:VOL. 2.C 2009060320121204VOL. 1. 52COBAL C.M. 424 (2.1) 52VP 0000190675 VM Inventario:3060ATENEO Descr.Fascicoli:VOL. 1.C 2009060320121204 01 04 06 07 08 41 52Derivationes83676UNICAS03872nam 2200433z- 450 991068841240332120210211(CKB)4100000002484755(oapen)https://directory.doabooks.org/handle/20.500.12854/42642(oapen)doab42642(EXLCZ)99410000000248475520202102d2017 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierCancer Metabolism: Molecular Targeting and Implications for TherapyFrontiers Media SA20171 online resource (114 p.)Frontiers Research Topics2-88945-322-7 Development of an effective anticancer therapeutic necessitates the selection of cancer-related or cancer-specific pathways or molecules that are sensitive to intervention. Several such critical yet sensitive molecular targets have been recognized, and their specific antagonists or inhibitors validated as potential therapeutics in preclinical models. Yet, majority of anticancer principles or therapeutics show limited success in the clinical translation. Thus, the need for the development of an effective therapeutic strategy persists. "Altered energy metabolism" in cancer is one of the earliest known biochemical phenotypes which dates back to the early 20th century. The German scientist, Otto Warburg and his team (Warburg, Wind, Negelein 1926; Warburg, Wind, Negelein 1927) provided the first evidence that the glucose metabolism of cancer cells diverge from normal cells. This phenomenal discovery on deregulated glucose metabolism or cellular bioenergetics is frequently witnessed in majority of solid malignancies. Currently, the altered glucose metabolism is used in the clinical diagnosis of cancer through positron emission tomography (PET) imaging. Thus, the "deregulated bioenergetics" is a clinically relevant metabolic signature of cancer cells, hence recognized as one of the hallmarks of cancer (Hanahan and Weinberg 2011). Accumulating data unequivocally demonstrate that, besides cellular bioenergetics, cancer metabolism facilitates several cancer-related processes including metastasis, therapeutic resistance and so on. Recent reports also demonstrate the oncogenic regulation of glucose metabolism (e.g. glycolysis) indicating a functional link between neoplastic growth and cancer metabolism. Thus, cancer metabolism, which is already exploited in cancer diagnosis, remains an attractive target for therapeutic intervention as well. The Frontiers in Oncology Research Topic "Cancer Metabolism: Molecular Targeting and Implications for Therapy" emphases on recent advances in our understanding of metabolic reprogramming in cancer, and the recognition of key molecules for therapeutic targeting. Besides, the topic also deliberates the implications of metabolic targeting beyond the energy metabolism of cancer. The research topic integrates a series of reviews, mini-reviews and original research articles to share current perspectives on cancer metabolism, and to stimulate an open forum to discuss potential challenges and future directions of research necessary to develop effective anticancer strategies.Cancer MetabolismMedicine and NursingbicsscCancer Metabolismepigenetic regulationglycolysisimmunotherapymetabolic reprogrammingmetastasisTumor microenvironmentWarburg effectMedicine and NursingShanmugasundaram Ganapathy-Kanniappanauth1352601BOOK9910688412403321Cancer Metabolism: Molecular Targeting and Implications for Therapy3186437UNINA